Dentsply Sirona cuts 2026 sales outlook to about $3.5 billion
Key Facts
On November 5, Dentsply Sirona cut its fiscal 2026 net sales outlook to about $3.5 billion and set adjusted earnings per share at $1.20 to $1.30. The earnings range excludes a one-time benefit of $0.17 per share from tariff refunds. The update came with the third-quarter results, which showed declines in sales and adjusted earnings compared with the same period last year. CEO Dan Scavilla said the company continued to make progress on its back-to-growth plan despite challenging industry conditions. The reduced outlook puts the performance of the different businesses at the center of the picture, as growth at Wellspect offset shrinking sales in the other segments.
Third-quarter net sales were $836 million, down 7.6% from $904 million a year earlier. By segment, sales of Connected Technology Solutions fell to $230 million from $259 million, while Core Dental Solutions sales declined to $343 million from $357 million. Orthodontic and Implant Solutions sales dropped to $171 million from $205 million in the third quarter of 2025. In contrast, Wellspect Healthcare sales rose to $92 million from $83 million, marking reported year-over-year growth of 10.1%, or 11.0% on a constant-currency basis. The company described the unit’s sales as a quarterly record, while sales declined across the other three segments.
Weaker sales were reflected in adjusted profitability measures: adjusted EBITDA was $146 million, down 13.3% from $167 million, and its margin fell to 17.3% from 18.4%. The company reported a GAAP diluted loss of $0.01 per share, compared with a loss of $2.14 a year earlier. Adjusted earnings per share were $0.29, down 29.4% from $0.42. The company said gross profit and adjusted EBITDA included a $39 million benefit from refining its estimate of unrealized profit in inventory. It said the adjustment reduced the reported net loss and increased adjusted net income by about $30 million, with no similar effect expected in future periods.
Operating cash flow fell to $32 million in the third quarter from $79 million a year earlier, a decline the company attributed mainly to unfavorable working-capital movements. Free cash flow was zero, compared with $40 million in the corresponding period of 2025. These figures add a liquidity dimension to the quarterly results, alongside lower sales and adjusted earnings. In a management comment, Scavilla said: "We continued to make progress on our back-to-growth plan during the third quarter despite challenging industry conditions." The company cited record Wellspect sales, progress in dental implants and endodontics, and expanded distributor reach in the United States as areas of progress.
For Wellspect, the company said it completed the U.S. launch of its Surity portfolio with the addition of the Surity Urology Management System. In contrast, its disclosure said the decline in endodontic sales was partly linked to lower volumes in Europe, the Middle East and Africa, and unfavorable pricing. The company added that changes in distributor inventory levels in the region could affect the volume and timing of future sales. These factors provide context for the divergence between growth in the healthcare unit and declining sales in some other businesses. The company’s stock, XRAY, closed at $9.16 on November 13, 2026, after closing at $9.24 on November 12 and $9.76 on November 11.